Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Top Cited Papers
Open Access
- 20 July 2016
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (9), 1283-1294
- https://doi.org/10.1016/s1470-2045(16)30167-x
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- National Institute for Health and Care Research
- National Institutes of Health (R01CA161026)
- NIHR Oxford Biomedical Research Centre
This publication has 21 references indexed in Scilit:
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated MalignanciesClinical Cancer Research, 2013
- Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationAnnals of Oncology, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersNature, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- The biology of Hodgkin's lymphomaNature Reviews Cancer, 2008
- PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphomaBlood, 2008
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000